Aspen Pharmacare has seen some financial weakness lately, but that hasn’t stopped it from pledging to make its largest manufacturing investment ever. The South African drugmaker says it will invest nearly $235 million in a facility to manufacture sterile anesthetics.
The announcement was made Friday at a government sponsored economic conference in the country. Stavros Nicolaou, Aspen senior executive offered few details, saying only that the R3.4 billion facility would be built at its Port Elizabeth manufacturing site and that it offered a high tech manufacturing niche “that presents both domestic and export opportunities.”
The company has said that the sterile anesthetics drug facility, along with a high containment facility that it opened in May, will allow Aspen to add 500 jobs at the Port Elizabeth site.
“Aspen has become one of the global leaders in a number of niche, specialty therapeutic segments, such as anesthetic, high potency and injectable anti-coagulant products, which present highly specialized public and private health opportunities,” Nicolaou said.
The $80 million, 23,000 square-meter, high potency facility opened last spring produces specialized meds like alkeran, leukeran and purinethol for cancer, as well as Parkinson’s disease drug benztropine.
The company’s share price has fallen by nearly half since September when it reported weaker than expected financial results. At the time it also said (PDF) it would sell its nutrition business to Lactalis Group for €740 million. Analysts told BusinessDay that in addition to the weak numbers, the sale of the nutrition business for half what some expected has weighed on the company’s share price.
By Eric Palmer
Source: Fierce Pharma
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.